Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats

Biomedicine and Pharmacotherapy

Volumn 63, Issue 9, 2009, Pages 635-642

  Fukushima, Keizo ^a   Shibata, Masakazu ^a   Mizuhara, Kazunori ^a   Aoyama, Hiroaki ^a   Uchisako, Rie ^a   Kobuchi, Shinji ^a   Sugioka, Nobuyuki ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Atazanavir; HIV; Hyperlipidemia; Pharmacokinetics

Indexed keywords

ATAZANAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TRANSPORT; DRUG UPTAKE; HALF LIFE TIME; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-HIV AGENTS; AREA UNDER CURVE; HALF-LIFE; HYPERLIPIDEMIAS; MALE; OLIGOPEPTIDES; PROTEIN BINDING; PYRIDINES; RATS; RATS, WISTAR;

EID: 70449117098     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.01.008     Document Type: Article

References (39)

1. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338 (1998) 853-860
2. Karon J.M., Fleming P.L., Steketee R.W., and De Cock K.M. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health 91 (2001) 1060-1068
3. d'Arminio Monforte A., Testa L., Adorni F., Chiesa E., Bini T., Moscatelli G.C., et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 12 (1998) 1631-1637
4. Cote H.C., Brumme Z.L., and Harrigan P.R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol 75 (2001) 589-594
5. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 (1998) F51-F58
6. Behrens G.M., Stoll M., and Schmidt R.E. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?. Drug Saf 23 (2000) 57-76
7. Bozzette S.A., Ake C.F., Tam H.K., Chang S.W., and Louis T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003) 702-710
8. Friedl A.C., Attenhofer Jost C.H., Schalcher C., Amann F.W., Flepp M., Jenni R., et al. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 14 (2000) 2790-2792
9. Behrens G.M., Meyer-Olson D., Stoll M., and Schmidt R.E. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 17 Suppl. 1 (2003) S149-S154
10. Hare C.B., Vu M.P., Grunfeld C., and Lampiris H.W. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 35 (2002) e111-e112
11. Hsyu P.H., Schultz-Smith M.D., Lillibridge J.H., Lewis R.H., and Kerr B.M. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 45 (2001) 3445-3450
12. Colonno R., Rose R., McLaren C., Thiry A., Parkin N., and Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 189 (2004) 1802-1810
13. Wood R., Phanuphak P., Cahn P., Pokrovskiy V., Rozenbaum W., Pantaleo G., et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 36 (2004) 684-692
14. Domingos H., da Cunha R.V., and Paniago A.M. Dyslipidaemia associated with the highly active antiretroviral therapy in AIDS patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir). Braz J Infect Dis 11 (2007) 290-292
15. Guffanti M., Caumo A., Galli L., Bigoloni A., Galli A., Dagba G., et al. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. Eur J Endocrinol 156 (2007) 503-509
16. Nguyen S.T., Eaton S.A., Bain A.M., Rahman A.P., Payne K.D., Bedimo R., et al. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy 28 (2008) 323-330
17. Mobius U., Lubach-Ruitman M., Castro-Frenzel B., Stoll M., Esser S., Voigt E., et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 39 (2005) 174-180
18. Bower S. Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure. J Pharm Pharmacol 34 (1982) 102-106
19. Danon A., and Chen Z. Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia. Clin Pharmacol Ther 25 (1979) 316-321
20. Oravcova J., Sojkova D., Fetkovska N., and Trnovec T. Factors influencing isradipine and amlodipine binding to human plasma lipoproteins. Blood Press Suppl 1 (1994) 61-64
21. Schuhmacher J., Buhner K., and Witt-Laido A. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 89 (2000) 1008-1021
22. Monks A., and Richens A. Plasma protein binding interaction between valproic acid and palmitic acid in vitro [proceedings]. Br J Clin Pharmacol 6 (1978) 448P
23. Terpstra A.H., Woodward C.J., and Sanchez-Muniz F.J. Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum. Anal Biochem 111 (1981) 149-157
24. Bollman J.L., Cain J.C., and Grindlay J.H. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med 33 (1948) 1349-1352
25. Gao W., Kishida T., Kimura K., Kageyama M., Sumi M., Yoshikawa Y., et al. Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry. Biomed Chromatogr 16 (2002) 267-273
26. Yoshikawa Y., Kato K., Sone H., and Takada K. Development and evaluation of noncompartmental pharmacokinetic analysis program WinHARMONY using Visual BASIC language having a function of automatic recognition vs time profile. Rinsho Yakuri 29 (1998) 475-487
27. Brocks D.R., Ala S., and Aliabadi H.M. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 27 (2006) 7-16
28. Aliabadi H.M., Spencer T.J., Mahdipoor P., Lavasanifar A., and Brocks D.R. Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function. AAPS J 8 (2006) E672-E681
29. Shayeganpour A., Jun A.S., and Brocks D.R. Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 26 (2005) 249-257
30. Eliot L.A., Foster R.T., and Jamali F. Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 16 (1999) 309-313
31. Wout Z.G., Pec E.A., Maggiore J.A., Williams R.H., Palicharla P., and Johnston T.P. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 46 (1992) 192-200
32. Whitlam J.B., and Brown K.F. Ultrafiltration in serum protein binding determinations. J Pharm Sci 70 (1981) 146-150
33. Barre J., Chamouard J.M., Houin G., and Tillement J.P. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 31 (1985) 60-64
34. Simon N., Dailly E., Combes O., Malaurie E., Lemaire M., Tillement J.P., et al. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br J Clin Pharmacol 45 (1998) 173-175
35. Fayet A., Beguin A., de Tejada B.M., Colombo S., Cavassini M., Gerber S., et al. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 30 (2008) 511-522
36. Sugioka N, Haraya K, Yuta M, Fukushima K, Takada K. Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats. Biol Pharm Bull 2008;32:269-75.
37. Ramaswamy M., Peteherych K.D., Kennedy A.L., and Wasan K.M. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother 45 (2001) 1184-1191
38. Wasan K.M., Rosenblum M.G., Cheung L., and Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 38 (1994) 223-227
39. Fernando-Warnakulasuriya G.J., Eckerson M.L., Clark W.A., and Wells M.A. Lipoprotein metabolism in the suckling rat: characterization of plasma and lymphatic lipoproteins. J Lipid Res 24 (1983) 1626-1638